Brain Arteriovenous Malformations: Spetzler-Martin, ARUBA Honestly Read, and Who Decides
An AVM found after a seizure is a different problem from one found after a hemorrhage — and ARUBA speaks only to the first. The-grade-in-a-table, the trial honestly read, and the referral that actually decides it.
Ruptured and unruptured AVMs are two different diseases — ARUBA only spoke to the second.
- →An AVM is a congenital artery-to-vein shunt without a capillary bed — a high-flow nidus that presents with hemorrhage (~half), seizures, headaches, or as an incidental find.
- →Hemorrhage risk averages roughly 2–4% per year, but the average hides the drivers: prior rupture, exclusively deep venous drainage, deep location, and associated aneurysms stack the risk multiply.
- →The Spetzler-Martin grade (size, eloquence, deep drainage) prices the surgical risk — it is a treatment-feasibility scale, not a rupture-risk scale, and the two are routinely confused.
- →ARUBA, for unruptured AVMs, found medical management alone beat intervention for death and symptomatic stroke over ~3 years — a result that held at 5-year follow-up — with real criticisms (intervention mix, follow-up horizon, generalizability) that temper but do not erase it.
- →Ruptured AVMs are different: rebleeding risk is front-loaded and treatment to secure the nidus is standard thinking. Every AVM — either kind — belongs in front of a multidisciplinary neurovascular team.
Two patients, same lesion, opposite problems. The first: a 24-year-old with a first seizure, MRI showing a 3 cm right frontal flow-void tangle — an unruptured AVM found by accident of physiology. The second: a 31-year-old with a lobar hemorrhage and a nidus at its rim. The first patient's enemy is decades of small annual risk and the temptation to intervene. The second's enemy is the next twelve months. Most of the confusion in AVM care comes from letting evidence about one patient answer for the other.
What an AVM is, and how it announces itself
A brain AVM is a developmental error of vasculogenesis: arteries feeding directly into veins through a tangled nidus, no capillary bed to drop the pressure. The veins arterialize, the shunt recruits flow, and the lesion lives under hemodynamic stress for the patient's whole life. Roughly half declare themselves with hemorrhage — typically lobar, in a young person, the scenario that puts AVM on every young-ICH differential alongside the entities in the cavernoma and CAA chapters.1 Most of the rest surface as seizures, headaches, or incidental findings. Catheter angiography remains the definitive map — feeders, nidus, drainage, and the associated flow-related aneurysms that matter below.
The rupture math
The teaching number — 2–4% per year — is real but lumpy.1 Risk concentrates when the anatomy says pressure and the history says precedent: prior hemorrhage (the strongest factor, especially in the first year), exclusively deep venous drainage, deep or infratentorial location, and intranidal or feeder aneurysms. A superficial unruptured AVM with cortical drainage sits near the bottom of the range; a previously-ruptured deep lesion with deep drainage compounds toward the top. Lifetime framing matters for a 24-year-old: even 2% per year is a large cumulative number over 50 years — which is precisely the intuition ARUBA forces us to test rather than assume.
Spetzler-Martin: a table for the right question
| Feature | Points | Note |
|---|---|---|
| Size | <3 cm = 1 · 3–6 cm = 2 · >6 cm = 3 | Largest nidus dimension |
| Eloquent location | No = 0 · Yes = 1 | Sensorimotor, language, visual cortex, thalamus, brainstem, deep nuclei |
| Deep venous drainage | No = 0 · Yes = 1 | Any deep draining vein counts |
| Grade | Sum 1–5: grades I–II generally favorable surgical candidates; grade III intermediate/heterogeneous; IV–V high surgical risk2 | |
Keep the scale honest about what it measures: operability, not rupture risk. A grade V AVM is dangerous to resect, not necessarily likely to bleed; deep drainage is the lone feature that appears on both lists.
ARUBA, honestly read
ARUBA randomized adults with unruptured AVMs to medical management alone versus interventional therapy (any modality) and stopped early: death or symptomatic stroke occurred in about 10% of the medical arm versus roughly 30% of the intervention arm over a mean ~33 months.3 Extended follow-up out to five years told the same story.4 The criticisms are substantive and should be said in the same breath: intervention was a heterogeneous mix light on surgery for favorable grades, follow-up remains short against a lifetime of annual risk, enrollment selection was debated, and the trial cannot speak to the low-grade lesion a high-volume surgeon removes with minimal morbidity. What survives the criticism is the direction: for the average unruptured AVM over the horizon actually measured, intervention hurt more than the disease did — a burden of proof that now sits on treating, not watching. Guidelines accordingly treat unruptured-AVM intervention as a selective, team-based call.1
ARUBA did not say "never treat an unruptured AVM." It said the treatment must beat 2% a year — and over the trial's horizon, it did not.
Ruptured AVMs are the other disease. After hemorrhage, rebleeding risk runs high in the early years, ARUBA does not apply, and securing the nidus — surgery, radiosurgery, embolization, or combinations, sequenced by the team — is standard thinking. The acute bleed itself is managed as any ICH (severity framed with the ICH score, care per the hemorrhage pathway), with the lesion addressed once the patient and brain allow.
The rest of the visit
- Seizures — treat AVM-related epilepsy like structural epilepsy: an antiseizure medication after a first seizure is generally warranted (a lesion is exactly the high-recurrence substrate), with drug choice logic borrowed from the post-stroke epilepsy chapter.
- Blood pressure and the basics — no trial forbids ordinary life, but hypertension control is sensible physiology in a high-flow lesion.
- The referral — every AVM deserves a multidisciplinary neurovascular conference (surgery, endovascular, radiosurgery) rather than a single-specialty verdict; modality mix and sequencing are exactly the decisions that go wrong in silos.
- The counseling — a young patient with an unruptured AVM is carrying a probability for decades: give the annual number, the modifiers, the ARUBA result and its limits, and a surveillance plan — the same "number, plan, permission to live" formula as the aneurysm visit.
The bottom line
Split every AVM conversation at the first question: has it bled? Ruptured lesions get secured, by a team, with urgency proportional to front-loaded rebleeding risk. Unruptured lesions get arithmetic — annual risk with its multipliers, Spetzler-Martin for what repair would cost, ARUBA for humility about intervening — and a team decision that usually lands on watching, sometimes on treating, and never on reflex. The tangle is congenital; the outcomes are mostly decided by the decisions.
Frequently asked questions.
What is a brain arteriovenous malformation?
A congenital tangle of arteries connecting directly to veins without an intervening capillary bed. The high-pressure shunt stresses the vessel walls for life, and the lesion can present with hemorrhage, seizures, headaches, or be found incidentally. Catheter angiography defines the feeders, nidus, and drainage.
What is the yearly bleeding risk of an AVM?
On average roughly 2–4% per year, but unevenly distributed: prior hemorrhage, exclusively deep venous drainage, deep or posterior fossa location, and associated aneurysms each raise it, and combinations compound. A previously ruptured AVM's risk is highest in the first years after the bleed.
What does the Spetzler-Martin grade mean?
It scores surgical difficulty — size (1–3 points), eloquent location (1), and deep venous drainage (1) — for a grade of I to V. Low grades are generally favorable surgical candidates; high grades carry high operative risk. It predicts what resection would cost, not how likely the AVM is to bleed.
What did the ARUBA trial show?
In adults with unruptured AVMs, medical management alone produced fewer deaths and symptomatic strokes than intervention over roughly three years, a difference that persisted at five-year follow-up. Its criticisms — heterogeneous interventions, short horizon versus lifetime risk, selection questions — are real, but the result shifted the burden of proof onto treating unruptured AVMs, which is now a selective multidisciplinary decision.
Does ARUBA apply to an AVM that has already bled?
No. ARUBA enrolled only unruptured AVMs. After hemorrhage, rebleeding risk is substantially higher and front-loaded, and securing the lesion — by surgery, radiosurgery, embolization, or a planned combination — is standard consideration by a neurovascular team.
Do AVM patients with a first seizure need seizure medication?
Generally yes — a structural vascular lesion is a high-recurrence substrate, so an antiseizure medication after a first AVM-related seizure is usually warranted, with drug selection weighing interactions and tolerability the same way as in other lesional epilepsies.
References.
- Derdeyn CP, Zipfel GJ, Albuquerque FC, et al. Management of Brain Arteriovenous Malformations: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017;48(8):e200-e224. PubMed
- Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. J Neurosurg. 1986;65(4):476-483. PubMed
- Mohr JP, Parides MK, Stapf C, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet. 2014;383(9917):614-621. PubMed
- Mohr JP, Overbey JR, Hartmann A, et al. Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicentre, non-blinded, randomised controlled trial. Lancet Neurol. 2020;19(7):573-581. PubMed
Related guides
Keep building the picture.
- ICH Score Severity framing when an AVM declares itself with hemorrhage.
- Cavernous malformations The low-flow cousin with its own rupture arithmetic.
- Unruptured intracranial aneurysm The same treat-versus-watch logic on a different lesion.
- Post-stroke epilepsy Drug-choice logic for lesional seizures, borrowed intact.
Article written by